Clinical trials: MEASLES DISEASE
Recurrent Non-Small Cell Lung Cancer
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
- Trial name
- NCT02919449
- Testing
- MV-NIS, Atezolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vyriad, Inc.
Measles, Mumps
Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092404
- Testing
- measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
ProQuad® Intramuscular vs Subcutaneous
Primary objective: To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00402831
- Testing
- ProQuad®
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
To compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children who receive an intranasal placebo mist…
- Trial name
- NCT00192491
- Testing
- FluMist
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15…
- Trial name
- NCT02184572
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 95 sites in United States, Estonia and 3 more
- Volunteers
- 1,742 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
Partially randomized, controlled Phase II study to evaluate safety, immunogenicity and dose response of the measles vaccine MVA mBN85B in healthy children aged 6 months to 6 years.
- Trial name
- NCT00891007
- Testing
- MVA-mBN85B, Rouvax
- Where
- South Africa
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Measles-Mumps-Rubella
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when…
- Trial name
- NCT01621802
- Testing
- Priorix, M-M-R II, Kinrix
- Where
- 67 sites in United States, South Korea and 1 more
- Volunteers
- 4,011 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
As measles-mumps-rubella (MMR) vaccination is established as routine childhood practice in most industrialised countries and varicella vaccination is now being introduced in many countries during the second year of life, a…
- Conditions
- Varicella, Rubella, Measles, Mumps
- Trial name
- NCT00353288
- Testing
- MeMuRu-OKA (study vacc), MMR, Varicella vacc (control)
- Where
- 39 sites in France, Germany and 1 more
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mumps, Rubella
Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra™) used in routine practice in children aged 12 months to 12 years living in the Philippines.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT01738841
- Testing
- Priorix-Tetra™, Safety data collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chikungunya Virus Infection
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection.
- Trial name
- NCT03807843
- Testing
- V184
- Where
- Puerto Rico
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Influenza
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
The primary objective of the study was to determine if intranasally administered influenza virus vaccine, CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles…
- Trial name
- NCT00192166
- Testing
- CAIV-T
- Where
- Singapore
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Polio, Measles
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
- Conditions
- Polio, Measles, Rubella, Mumps
- Trial name
- NCT07338851
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Measles, Varicella
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
This study is undertaken to generate clinical data on GSK Biologicals' combined measles-mumps-rubella-varicella vaccine manufactured with measles and rubella obtained from newly established working seed viruses which are one…
- Conditions
- Measles, Varicella, Mumps, Rubella
- Trial name
- NCT00892775
- Testing
- Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation
- Where
- 6 sites in Singapore, Taiwan
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis A
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a varicella (chickenpox) vaccine in children as young…
- Trial name
- NCT00197015
- Testing
- Havrix®, M-M-R®II, VARIVAX®
- Where
- 42 sites in United States
- Volunteers
- 1,474 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
Eligible,healthy infants who have finished the 3-dose-schedule of sIPV+DTaP combined vaccination clinical trial (NCT04054882) will be recruited and divided into 4 groups, and will receive vaccination at the age of 18-month-old as…
- Trial name
- NCT04638985
- Testing
- sIPV+DTaP+MMR, sIPV, DTaP
- Where
- 3 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Measles
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).
- Trial name
- NCT00109278
- Testing
- V205C, measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
This study will compare the safety, tolerability, and immunogenicity of measles, mumps, rubella, and varicella (MMRV) vaccine made with an alternative manufacturing process with those of the 2006 process
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT01536405
- Testing
- MMRV (AMP), MMRV (2006 process)
- Volunteers
- 1,412 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mumps, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Since measles-mumps-rubella (MMR) and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life, a combined measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine…
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00352898
- Testing
- MeMuRu-OKA (study vac), MMR, Varicella vacc (control)
- Where
- 6 sites in Canada, Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline